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Purpose: To evaluate the effect of 3% trehalose as an adjuvant in the standard treatment after 
laser-assisted in situ keratomileusis.
Design: Interventional prospective comparative single-blind study.
Setting: Department of Ophthalmology, Hospital Quirón Zaragoza, Spain.
Methods: A total of 26 eyes (13 patients) were included, of which 12 eyes (group 1) received 
conventional treatment with lubricant drops of hyaluronic acid (0.15%) and 14 eyes (group 2) 
received, additionally, an ophthalmic solution of 3% trehalose. Pre- and postoperative quality-
of-life tests and vital stains, tear breakup time, and osmolarity measurements were made.
Results: We obtained statistically significant differences between the groups in the Symptom 
Assessment in Dry Eye test in all visits with respect to severity, and in the postoperative day 1 
visit with respect to frequency, in all cases favoring the trehalose treatment. The values of 
osmolarity were not significantly different between groups. However, we did find significant 
differences in the Oxford scale in day 90 for the trehalose treatment (P,0.001), and in the 
National Eye Institute scale in day 30 (P=0.02).
Conclusion: The results of this exploratory study indicate that the adjuvant treatment with 
3% trehalose could be superior with respect to the standard treatment, with improvements in 
the objective and subjective parameters of tear quality.
Keywords: dry eye syndrome, trehalose, hyaluronic acid, LASIK, osmolarity
Introduction
Laser-assisted in situ keratomileusis (LASIK) is currently the most common refractive 
surgery treatment performed in the USA, with .600,000 working-age patients treated 
yearly.1 The quick visual rehabilitation after the procedure and highly predictable 
outcomes make this technique one of the most widely distributed worldwide. However, 
postsurgical adverse effects such as dry eye can occur with a prevalence that has been 
estimated between 0.8% and 40%.1–4 The damage to the afferent sensory innervation 
caused by the cutting of the corneal flap and the stromal ablation determines a loss of 
corneal sensitivity with reduced tear production, decreased blinking rate, altered tear 
film, and loss of goblet cells.5,6 Although most patients suffer from dry eye symptoms 
only temporally, some patients can develop a chronic condition, which significantly 
undermines their satisfaction with the surgery.
Dry eye disease is a multifactorial syndrome that causes discomfort, visual dis-
turbances, and tear film instability, which can potentially damage the ocular surface. 
It is accompanied by increased osmolarity of the tear film and inflammation of the 
ocular surface.7 Treatment is based on topical application of tear-substitute compounds 
containing various polymers and viscosity agents that provide lubrication to the tear 
surface. However, there is no perfect formula for the optimal replacement of the tear 
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film, and most commercial formulations just mimic the 
composition of human tears.8
Trehalose, considered an osmoprotectant, is a disaccharide 
derived from glucose. It is found naturally in many organisms 
and it has been recognized as key to anhydrobiosis, that is, the 
ability of an organism to survive long periods of desiccation.9 
Its osmoprotectant function in eukaryotic cells includes the 
stabilization of the lipid bilayers and labile proteins to desic-
cation, and protection against oxidative stress.10
The development of new therapies to recover tear homeo-
stasis in the shortest time possible after surgery is of special 
interest to the ophthalmologist. The objective of our study 
was to determine the effects of treatment with trehalose as an 
adjuvant osmoprotectant agent after standard LASIK, using 
objective and subjective parameters of ocular dryness.
Patients and methods
This interventional, prospective, comparative, single-blind 
study included 26 eyes of 13 patients who underwent 
bilateral LASIK between December 2013 and June 2014 in 
the Department of Ophthalmology at the Hospital Quirón 
(Zaragoza, Spain). The gender distribution of patients was 
92.3% males and 7.7% females. The age of the patients 
ranged between 29 and 43 years (mean ± standard deviation 
[SD]: 35.23±5.23).
This study adhered to the principles of the Declaration 
of Helsinki and was approved by the Ethics Committee of 
Aragon (CEICA), Institute of Health Research (IIS, Aragón, 
Spain). All patients were informed orally and in writing of 
the surgical procedure, potential risks and complications, 
and implications of accepting this study.
The study included 26 eyes of 13 patients whose consent 
was obtained verbally and in writing. Patients who met the 
inclusion criteria of the study were candidates for LASIK 
surgery aged between 18 and 45 years. Exclusion criteria 
rejected patients with systemic treatments or processes that 
could alter the results in the study, such as acne rosacea or 
taking oral contraception; and ophthalmological criteria 
such as refraction defects higher than 3 sphero-cylindrical 
diopters; wearing contact lenses before the screening 
visit (7 days in the case of soft contact lenses, 21 days in 
case of hard contact lenses); treatments for eye diseases, 
such as uveitis, corneal herpes, trauma, or corneal infec-
tion during the 90 days prior to the intervention; changes 
in eyelid anatomy or blepharitis; patients with corrected 
visual acuity (VA) ,20/20 Snellen; or patients with con-
firmed diagnosis of dry eye in the preoperative visit. Dry 
eye was defined by the presence of one or more of the 
following criteria: decreased basal tear secretion (Schirmer 
with anesthesia ,10 mm/5 minutes); a tear breakup time 
(TBUT) value ,8 seconds; reduced blinking rate 
(,7 per minute) or a score .1 in the Oxford scale in the vital 
stain tests (fluorescein and lissamine green). The appearance 
of any complication during surgery was also an exclusion 
criterion. Both preoperative and postoperative examination 
at 1, 7, 30, and 90 days included symptom assessment scales 
such as the overall score of the Ocular Surface Disease Index 
(OSDI,11 symptoms and quality of life in everyday tasks, 
scored from 0 to 100) and the Symptom Assessment in Dry 
Eye (SANDE,12 scale of frequency of symptoms, quantified 
by an analogic visual scale) questionnaires. Tear osmolarity 
was measured from 50 nL of the temporal inferior lagrimal 
meniscus, as determined by Tearlab® (OcuSense, Inc., San 
Diego, CA, USA). We measured objective indices of ocular 
dryness with lissamine green staining (Lissaver Plus strips, 
Contopharma, Interlaken, Switzerland) quantitated by the 
van Bijsterveld13 and Oxford14 scales, fluorescein staining 
(fluorescein 2%, Alcon Cusí, El Masnou, Spain) quantitated 
by the National Eye Institute (NEI)15 scale, and TBUT, 
respecting this scale sequence. Staining with both dyes was 
applied with stripes on the upper bulbar conjunctiva.
With respect to functional variables, we quantified 
monocular best corrected distance visual acuity (6 m) in the 
preoperative visit and spontaneous monocular VA in each 
of the postoperative visits by the ETDRS® system. Scanning 
conditions for all distances were identical and patients were 
instructed to apply the last drop of treatment 2 hours before 
scanning in a quiet and illuminated room in photopic condi-
tions (70 cd/m2).
All patients underwent sequential binocular surgery. 
The procedure involved creating a flap 120 µm in thickness, 
9.5 mm in diameter, and a 50° top hinge with a macera-
tor Zyoptix XP microkeratome (Bausch & Lomb, Berlin, 
Germany) after administration of topical anesthetic oxy-
buprocaine, and placement of an eye speculum and sterile 
cloth. Ablation to achieve emmetropia was conducted with 
the excimer laser system Visx Star S4® (Abbott Laborato-
ries, Inc., Abbott Park, IL, USA) with a treatment diameter 
of 6.5 mm. Later the interface was abundantly irrigated with 
balanced saline solution and repositioning of the flap in the 
surgical bed. Postoperative treatment with dexamethasone 
(1 mg/mL) and topical tobramycin (3 mg/mL; Tobradex®, 
Alcon-Cusi, El Masnou, Spain) every 2 hours was gradually 
reduced during 10 days. Patients were assigned randomly 
to two treatment groups of different lubricants. In group 1, 
lubricating drops with hyaluronic acid (HA; 0.15% 
 
Cl
in
ica
l O
ph
th
al
m
ol
og
y 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
15
5.
21
0.
59
.2
10
 o
n 
22
-M
ar
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Ophthalmology 2017:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
349
Trehalose in lasiK
Hyabak®, Thea, Clermont-Ferrand, France) were given 
every 2 hours during the first 10 days and 6 times a day from 
day 11 until 3 months postsurgery. In group 2, the same 
dosage of Hyabak plus an aqueous ophthalmic solution of 
3% trehalose (Thealoz®, Thea, Clermont-Ferrand, France) 
was prescribed 4 times a day, always administered 5 minutes 
before the HA-rich solution and starting the application 
3 days before surgery.
Statistical analysis
Data analysis was performed with the Statistical Package for 
Social Sciences (SPSS, version 19.0, Chicago, IL, USA). We 
performed descriptive statistics of all variables collected, 
with frequency tables for nominal variables, and measures 
of central tendency and dispersion for continuous variables 
(confidence intervals of 95%).
We started by performing a baseline homogeneity 
analysis of the treatment groups. We used the Fisher’s exact 
test for comparison of categorical variables, the Mann–
Whitney U-test for comparison of ordinal variables, and the 
Student’s t-test for continuous variables.
Even though we did not detect statistically significant 
differences between groups at baseline, in order to reduce 
intrasubject variability and increase statistical power, we 
chose to contrast paired data corrected to the presurgery 
values. To compare continuous variables we used analysis 
of covariance comparing treatment groups by taking into 
account baseline measurements. In the case of ordinal 
variables we used the Wilcoxon sign test. For all tests we 
established the level of significance at P,0.05.
Results
Twelve eyes were assigned to the treatment group 1 and 14 
eyes assigned to group 2, and all completed the study.
Group 1 was composed entirely of men with a mean age of 
36.17±4.36 years. No statistically significant differences were 
found with respect to group 2, where the proportion of men 
was 85.71% (P.0.05, Fisher) and a mean age of 34.43±6.11 
years (P.0.05, t-test). The average corrected refractive defect 
was 3.5 myopic diopters (D) in terms of spherical equivalent, 
with a range from 2.5 to 4 D. We also obtained no differences 
between the groups (P=0.134, Mann–Whitney U-test).
Table 1 shows the preoperative values for all variables 
for both study groups. No statistically significant baseline 
differences can be observed for any of them.
Regarding the test of subjective assessment of symp-
toms of dry eye, no statistically significant differences 
were observed between the groups with the OSDI test. The 
SANDE test showed significant differences in the frequency 
on day 1, and on all visits with respect to severity of symp-
toms for treatment with trehalose (Table 2).
No statistically significant differences were detected 
regarding tear osmolarity between the groups throughout 
the postoperative visits. We noted that the highest values of 
osmolarity were registered 24 hours after surgery. The low-
est values were observed on the second visit in both groups 
(Table 2; Figure 1).
Table 2 shows the mean, SD, and statistical significance 
of values of lissamine green (van Bijsterveld and Oxford 
scales) and fluorescein (NEI scale) staining, in addition to the 
TBUT values and osmolarity. We could observe significant 
differences on day 90 of the Oxford scale in favor of treat-
ment with trehalose (P=0.00, Mann–Whitney U-test) and 
on day 30 of the NEI scale (P=0.02, Mann–Whitney U-test) 
also for the same treatment group.
Table 3 presents the values of tear osmolarity and staining 
with lissamine green (Oxford scale) for each eye explored in 
the preoperative and all postoperative visits.
Table 1 Preoperative values (mean ± standard deviation) and range of variables with respect to dry eye
Diagnostic tests Group 1 Group 2 P-value
Ocular surface Disease index 6.94±9.29 (0–25), n=6 7.08±12.24 (0–33.3), n=7 0.98*
sanDe (symptom frequency) 1.92±2.11 (0–6), n=6 0.71±0.76 (0–2), n=7 0.184*
sanDe (severity) 1.25±1.47 (0–4), n=6 0.29±0.49 (0–1), n=7 0.13*
Osmolarity 302.4±13.59 (277–325), n=12 310.14±14.78 (288–342), n=14 0.18*
lissamine green staining (van Bijsterveld) 1.25±1.06 (0–3), n=12 0.69±0.75 (0–2), n=14 0.18**
lissamine green staining (Oxford) 0.5±0.52 (0–1), n=12 0.43±0.51 (0–1), n=14 0.74**
Fluorescein staining (national eye 
institute/industry Workshop)
0.08±0.29 (0–1), n=12 0.07±0.27 (0–1), n=14 0.96**
Tear breakup time 13.83±6.01 (7–25), n=12 11.11±6.63 (5.5–26), n=14 0.29*
schirmer with anesthesia 16±5.16 (10–25), n=12 15.36±1.34 (15–20), n=14 0.66*
Notes: *student’s t-test; **Mann–Whitney U-test; P,0.05. Data shown as mean ± standard deviation (range).
Abbreviation: sanDe, symptom assessment in Dry eye.
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Table 2 Postoperative values (mean ± SD) and statistical significance between the groups
Diagnostic 
tests
N Day 1 Day 7 Day 30 Day 90
Mean ± SD Significance Mean ± SD Significance Mean ± SD Significance Mean ± SD Significance
OsDi
ha + trehalose 7 11.21±18.8 0.11* 7.14±3.9 0.03* 3.27±2.6 0.035* 2.68±2.88 0.16*
ha 6 31.72±24.1 16.76±9.2 11.46±8.6 5.9±4.83
OsDi (difference with baseline)
ha + trehalose 7 4.13±26.1 0.09** 0.06±13.8 0.22** -3.81±13.6 0.32** -4.4±13.5 0.66**
ha 6 24.77±29.7 9.82±11.1 4.51±7.7 -1.04±6.3
sanDe frequency
ha + trehalose 7 1.14±1.1 0.03* 1.71±1.2 0.3* 1.50±1.7 0.31* 0.29±0.4 0.03*
ha 6 4.0±2.8 2.92±2.6 2.67±2.2 1.33±1.1
sanDe frequency (difference with baseline)
ha + trehalose 7 0.43±1.1 0.01** 1.0±1.6 0.09** 0.79±1.9 0.12** -0.43±0.6 0.06**
ha 6 2.08±3.9 1.0±3.5 0.75±3 -0.58±2.0
sanDe severity
ha + trehalose 7 0.57±0.8 0.01* 0.79±0.7 0.01* 0.50±0.5 0.02* 0.36±0.5 0.01*
ha 6 3.50±2.1 2.08±0.9 1.92±1.3 1.17±0.5
sanDe severity (difference with baseline)
ha + trehalose 7 0.29±0.8 0.00** 0.50±0.8 0.01** 0.21±0.7 0.01** 0.07±0.4 0.02**
ha 6 2.25±2.9 0.83±1.9 0.67±1.9 -0.08±1.6
Osmolarity
ha + trehalose 14 311.6±17.6 0.54* 306.07±11.3 0.48* 308.86±16.7 0.73* 306.21±9.6 0.65*
ha 12 308.17±9.3 302.90±9.9 306.92±10.3 304.58±8.2
Osmolarity (difference with baseline)
ha + trehalose 14 1.50±14.6 0.25** -4.07±16.8 0.11** -1.29±16.6 0.3** -3.93±11.8 0.26**
ha 12 5.75±16.2 2.50±17.6 4.50±15.9 2.17±11.8
Va
ha + trehalose 14 0.02±0.04 1* 0.03±0.04 0.85* 0.01±0.05 0.16* 0.0±0.0 0.28*
ha 12 0.02±0.04 0.03±0.05 0.03±0.04 0.01±0.03
Va (difference with baseline)
ha + trehalose 14 0.02±0.04 1** 0.03±0.04 0.85** 0.01±0.05 0.16** 0.0±0.0 0.28**
ha 12 0.02±0.04 0.03±0.05 0.03±0.04 0.01±0.03
van Bijsterveld scale
ha + trehalose 14 2.43±2.0 0.34$ 3.07±2.7 0.81$ 1.79±1.9 0.06$ 1.29±1.3 0.01$
ha 12 3.08±1.7 3.17±1.8 3.00±1.6 3.0±1.8
van Bijsterveld scale (difference with baseline)
ha + trehalose 14 1.46±1.5 0.61$ 2.08±2.6 0.8$ 1.00±1.7 0.27$ 0.46±1.1 0.12$
ha 12 1.83±1.7 1.92±1.7 1.75±1.4 1.75±2.0
Oxford scale
ha + trehalose 14 0.86±0.8 0.05$ 1.07±1 0.16$ 0.75±0.7 0.02$ 0.36±0.5 0.00$
ha 12 1.42±0.5 1.58±0.7 1.42±0.5 1.50±0.7
Oxford scale (difference with baseline)
ha + trehalose 14 0.43±0.8 0.09$ 0.64±1.1 0.27$ 0.42±0.7 0.15$ -0.07±0.6 0.00$
ha 12 0.92±0.7 1.08±0.9 0.92±0.8 1.0±0.9
nei/industry Workshop scale
ha + trehalose 14 1.21±1.3 0.91$ 2.07±2.8 1$ 0.07±0.3 0.0$ 0.21±0.4 0.07$
ha 12 1.33±1.7 2.08±2.9 1.50±1.7 2.0±3.4
nei/industry scale (difference with baseline)
ha + trehalose 14 1.14±1.3 0.96$ 2.0±2.8 1$ 0.00±0.4 0.02$ 0.14±0.5 0.12$
ha 12 1.25±1.8 2.0±2.9 1.42±1.8 1.92±3.4
TBUT
ha + trehalose 14 6.29±5.3 0.36* 6.18±6.3 0.73* 9.0±7.6 0.25* 6.86±5.7 0.9*
ha 12 4.79±1.8 6.92±4.0 6.21±3.2 6.58±4.8
TBUT (difference with baseline)
ha + trehalose 14 -4.82±2.3 0.74** -4.93±1.7 0.44** -2.11±3.4 0.99** -4.25±5.6 0.53**
ha 12 -9.04±6.8 -6.92±4.7 -7.63±5.4 -7.25±7.0
Notes: *student’s t-test; **anOVa paired test; $Mann–Whitney U-test.
Abbreviations: ha, hyaluronic acid; nei, national eye institute; OsDi, Ocular surface Disease index; sanDe, symptom assessment in Dry eye; sD, standard deviation; 
TBUT, tear breakup time; Va, visual acuity; anOVa, analysis of variance.
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Discussion
Postoperative dry eye is still a challenge for the refractive 
surgeon. Its development affects the satisfaction of our 
patients, who often require immediate results and quick 
recovery. We have no accurate diagnostic test that can predict 
which patients will suffer clinically relevant dryness after 
refractive surgery. Dry eye disease symptoms may occur 
postoperatively even in individuals with a preoperative 
study within normal parameters. Some studies have sug-
gested that the risk factors include the ablation depth and 
thickness of the flap, the degree of preoperative myopia,16 
female sex,17 or the position of the hinge.18 Although the 
mechanisms involved in the development of dry eye are 
not fully understood, some etiopathogenic mechanisms that 
have been proposed are the alteration in the sensory input 
secondary to the flap transection and ablation, the reduction in 
the blinking reflex, drug toxicity, altered conjunctival goblet 
glands caused by microkeratome suction, or modification of 
the central corneal conformation.19
The strong decrease in the postoperative TBUT found 
in our study for both groups is consistent with the results 
published by other authors.20,21 This instability has been 
suggested as responsible for the reduction in VA associated 
with increased higher-order aberrations even when the 
sphero-cylindrical correction has been successful.22 Despite 
this alteration of the tear film, the VA of our patients was not 
diminished in any of the groups and questionnaires for symp-
toms related to visual satisfaction were not rated negatively 
by any of the individuals studied, although the score could 
be confounded by the refractive correction of the subject and 
the satisfaction derived from it.
???
???
???
???
???
???
???
???
???
??? ?????????
???
????
?????
??
???
??
????? ????? ?????? ??????
Figure 1 Mean tear osmolarity values measured in patients treated with Thealoz® 
(blue) and without Thealoz® (orange).
Table 3 Osmolarity and lissamine green staining measurements throughout the study
Patient Eye Visit
Preoperative Day 1 Day 7 Day 30 Day 90
OSM LG OSM LG OSM LG OSM LG OSM LG
1 right 295 0 300 1 288 0 296 0 302 0
left 303 0 305 1 301 1 288 1 297 1
2 right 299 0 294 1 292 1 291 1 305 2
left 311 1 310 2 296 1 290 1 300 1
3 right 304 0 311 1 324 1 313 1 300 1
left 306 0 308 1 291 1 316 1 294 1
4 right 302 0 302 0 289 0 282 0 296 0
left 288 1 294 1 300 0 286 1 294 1
5 right 308 1 311 2 301 1 319 1 300 1
left 317 1 323 2 296 2 321 2 323 2
6 right 311 1 316 1 300 2 335 2 295 2
left 342 1 310 2 317 2 325 2 314 1
7 right 277 1 306 2 305 2 305 1 298 1
left 281 1 321 1 310 2 304 2 300 1
8 right 306 0 316 1 303 1 304 1 313 1
left 295 1 302 1 302 1 316 1 308 1
9 right 316 1 301 1 298 1 303 1 326 0
left 297 0 300 0 330 1 319 1 298 0
10 right 307 1 326 0 308 1 317 0 306 0
left 322 1 315 1 304 1 326 0 307 0
11 right 300 0 294 1 297 2 300 2 301 2
left 325 1 302 2 309 1 304 2 313 2
12 right 334 0 365 2 306 3 300 1 315 1
left 314 0 312 1 308 3 328 1 311 1
13 right 304 0 301 1 316 2 310 1 315 0
left 307 0 316 1 317 2 312 2 311 1
Abbreviations: OsM, osmolarity; lg, lissamine green staining.
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The absence of differences observed between the two 
groups for tear osmolarity is an expected result because the 
surgical aggression was the same for all patients. The lowest 
levels of osmolarity in the ocular surface of the patients were 
the same for both groups and coincided with the time of the 
highest frequency of instillation of Hyabak, a hypotonic 
solution (202±2 mOsm/L). It should be noted that all patients 
were instructed not to apply the lubricant in the 120 minutes 
prior to any of the visits in order to better quantify the 
changes generated in the ocular surface. The decrease in 
aqueous secretion with a resulting decrease of TBUT, also 
with no differences between the groups, may be responsible 
for the larger concentration of tear film solutes in the patients. 
Despite the absence of differences for these variables, we did 
observe that patients with higher preoperative osmolarity 
were those showing a stronger alteration in staining. Of these, 
those who were in the group with trehalose were the ones 
that most benefited from this treatment (Table 3).
The most relevant results of this study are those concern-
ing the vital stains. As can be seen in Table 2, we found 
larger differences in the variables that evaluate cell vitality 
between the two groups. Thus, the interaction of trehalose 
with membrane lipids could provide extra protection against 
surgical trauma and increased osmolarity, resulting in lower 
rates of inflammation and cell death.23
Previous studies have highlighted the benefits of treat-
ment with trehalose in vitro,24,25 ex vivo,26 or in live-animal 
models,27 and in subjects with dry eye.28–30 However, this 
is the first study that evaluates the usefulness of trehalose 
after LASIK.
The results of objective variables were supported by 
the subjective tests that the subjects completed during the 
study. The improvement in the staining tests thus correlated 
with greater sense of comfort in our patients, and lower 
perception of symptoms and severity, in the SANDE test. 
In the OSDI test, despite no statistical differences between 
groups, the scores reached baseline levels in the exploration 
of day 7, and were even better in subsequent visits. However, 
in the group treated only with HA, we observed a trend of 
slower recovery.
The major limitation of the study is the small number 
of patients. Several variables analyzed, such as those of the 
van Bijsterveld or Oxford scales on day 30, showed values 
barely significant. We are aware that a higher number of 
patients would have improved the statistical power and 
therefore the chances of finding differences between the two 
groups. In addition, the gender unbalance in our study could 
be another important limitation to the interpretation of the 
data because female patients could be at higher risk for dry 
eye syndrome.17 Finally, we compared results between the 
patients and not between eyes of the same patient to avoid 
potential confusions in the treatment. We considered that 
indicating a different postsurgical treatment for each eye in 
the same individual would add stress to the patient.
Conclusion
In conclusion, we observed time-dependent clinical changes 
in both intervention groups, which resulted in the appearance 
of a transient postoperative dry eye after LASIK. However, 
the differences found for some variables indicate that the 
recovery of the tear and cell homeostasis was best for the 
group treated with 3% trehalose as an adjuvant, concluding, 
therefore, the possible superiority of such treatment after 
LASIK compared to treatment with HA solution exclusively. 
Further investigation on a larger group of patients will be 
necessary to determine if adjuvant treatment with trehalose 
is a good choice for patients undergoing refractive surgery.
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